Comparative Pharmacology
Head-to-head clinical analysis: HALOTESTIN versus ORETON METHYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOTESTIN versus ORETON METHYL.
HALOTESTIN vs ORETON METHYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluoxymesterone is a synthetic androgen that binds to androgen receptors, activating gene transcription and promoting protein synthesis, leading to anabolic and androgenic effects.
Methyltestosterone is a synthetic androgen that binds to androgen receptors, activating transcription of androgen-responsive genes, leading to increased protein synthesis, muscle growth, and secondary sexual characteristic development.
10-20 mg orally three to four times daily for replacement therapy; 2-10 mg orally daily for delayed puberty in males.
10-50 mg orally or buccally 1-3 times daily; or 25-100 mg IM every 2-4 weeks.
None Documented
None Documented
Terminal elimination half-life: 9.6 hours. Clinical context: Steady-state achieved after ~48 hours.
Terminal half-life approximately 2.7–3.8 hours; brief due to rapid hepatic metabolism.
Renal: 90% as glucuronide and sulfate conjugates; fecal: 10%.
Primarily renal as conjugated metabolites; ~90% urinary, ~6% fecal within 4 days.
Category C
Category C
Androgen
Androgen